• Sanofi: Wouldn't trade our pipeline     Thursday, 20 Nov 2014 | 1:47 PM ET

    Sanofi's global R&D President Dr. Elias Zerhouni, says he wouldn't trade his company's pipeline with anybody in the industry, and discusses the upcoming drug launches.

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral, a court filing showed. Ranbaxy had filed a lawsuit against the U.S. Food and Drug Administration last week for revoking tentative approvals it gave the company to make...

  • Soaring generic drug prices draw Senate scrutiny Thursday, 20 Nov 2014 | 8:32 AM ET

    WASHINGTON— Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington lawmakers. Members of the Senate meet Thursday to scrutinize the recent, unexpected trend among generic medicines, which are copies of...

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed. Ranbaxy had sought the restraining order against Dr Reddy's Laboratories and U.S. firm Endo International Plc in a lawsuit it filed...

  • Nov 20- Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday. Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels,...

  • Nov 18- The estimated average cost of developing an approved new drug has more than doubled to more than $2.5 billion from a 2003 estimate by Tufts University, but critics questioned the figure and noted the school's strong financial ties to the pharmaceutical industry. The Tufts Center for the Study of Drug Development, located in Boston, in 2003 estimated the...

  • AstraZeneca trumpets strength in drug development Tuesday, 18 Nov 2014 | 3:24 AM ET
    British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England.

    AstraZeneca said it had made good progress in developing a pipeline of new drugs.

  • Outbreaks like Ebola will happen again: NIH Monday, 17 Nov 2014 | 3:57 PM ET
    File photo: A young man, dressed in a biohazard costume, stands on the corner of 546 West 147th Street in October 2014 in New York City after an American doctor carrying the ebola virus was admitted to Bellevue Hospital

    NIH's Dr. Francis Collins and Milken Institute Chairman Mike Milken make the case for medical research funding to stop outbreaks like Ebola.

  • US, German drugmakers team up on cancer medicines Monday, 17 Nov 2014 | 1:47 PM ET

    Under their agreement, New York- based Pfizer will pay Merck KGaA $850 million initially and up to $2 billion total, based on how many drugs are approved and future revenue levels. Pfizer said it will take a charge for the $850 million payment, cutting into profit this year, so it's lowered its 2014 earnings forecast by a dime, to a range of $1.40 to $1.49 per share.

  • *Novartis already has Google contact lens, smart pill deals. LONDON, Nov 17- Talent spotters from Novartis AG, charged with bringing new ideas into the organisation, are casting their net beyond biotech into the wider pool of wearable, or even edible, technology. The Swiss group has already taken tentative steps, signing a deal with Google Inc in July to develop...

  • Zoetis attractive & durable: Pro     Monday, 17 Nov 2014 | 12:35 PM ET

    Shares of Zoetis are on the move after Actavis announced it is buying Allergan. Mark Schoenbaum, Evercore ISI senior managing director, discusses if the company could be bought.

  • DEA painkiller probe targets NFL medical staffs Monday, 17 Nov 2014 | 11:46 AM ET
    Joe Horn

    DEA agents questioned medical-staff members from several NFL teams in a continuing investigation into distribution of painkillers, The NYT reports.

  • CHICAGO, Nov 17- Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck& Co's Zetia, according to data from a clinical trial presented on Monday. Alirocumab, developed along with French drugmaker Sanofi, belongs to a new...

  • Actavis, Allergan are a 'strategic fit'     Monday, 17 Nov 2014 | 11:40 AM ET

    Áine Slowey, senior analyst at Datamonitor Healthcare, discusses Actavis' decision to buy Allergan for $65.5 billion, saying that Actavis has demonstrated a "strong commitment" to R&D.

  • Why Allergan never engaged Valeant     Monday, 17 Nov 2014 | 9:36 AM ET

    Allergan chairman & CEO David Pyott, explains why Allergan never engaged Valeant Pharmaceuticals and what's next for the newly combined companies.

  • Actavis CEO: Huge commitment to R&D     Monday, 17 Nov 2014 | 9:32 AM ET

    CNBC's Jim Cramer speaks to Brent Saunders, Actavis CEO, and David Pyott, Allergan chairman & CEO, about the growth and R&D budget of the combined companies going forward.

  • Actavis to spend $66 billion on Allergan Monday, 17 Nov 2014 | 9:32 AM ET

    Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products. Actavis and the company it outbid for Allergan, Valeant Pharmaceuticals, both have grown rapidly in recent years through multibillion dollar acquisitions of other drugmakers.

  • CNBC's David Faber speaks to David Pyott, Allergan chairman & CEO, and Brent Saunders, Actavis CEO about their deal worth roughly $66 billion and what it means for shareholders.

  • NEW YORK— Pharmaceutical giant Actavis to buy Botox maker Allergan for $66 billion in cash-and-stock.

  • Study lifts cloud over heart drugs Zetia, Vytorin Monday, 17 Nov 2014 | 8:53 AM ET

    CHICAGO— A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. Merck& Co.' s ezetimibe, which went on sale in 2002, lowers cholesterol in a different way. The drug won Food and Drug Administration approval for lowering LDL, but some studies suggested that might not translate to fewer heart attacks and strokes.